Publication:
Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol

Simple item page
dc.contributor.authorSalvador, Fernando
dc.contributor.authorLucas-Dato, Ana
dc.contributor.authorRoure, Silvia
dc.contributor.authorArsuaga, Marta
dc.contributor.authorPérez-Jacoiste, Asunción
dc.contributor.authorGarcía-Rodríguez, Magdalena
dc.contributor.authorPérez-Molina, José A
dc.contributor.authorBuonfrate, Dora
dc.contributor.authorSaugar, Jose Maria
dc.contributor.authorMolina, Israel
dc.contributor.funderSociedad Española de Enfermedades Infecciosas y Microbiología Clínica
dc.date.accessioned2022-04-18T07:55:01Z
dc.date.available2022-04-18T07:55:01Z
dc.date.issued2021-06-27
dc.description.abstractStrongyloidiasis affects an estimated 600 million people worldwide, especially in tropical and subtropical areas. Single-dose ivermectin treatment has shown to be effective among immunocompetent patients with uncomplicated strongyloidiasis. Here, we present the protocol of the ImmunoStrong study, a prospective observational study aiming to evaluate the effectiveness and safety of a single-dose ivermectin for treatment of uncomplicated strongyloidiasis in immunosuppressed patients. The secondary objectives are to assess accuracy of molecular techniques for the follow-up of these patients and to determine the population pharmacokinetics of ivermectin. The information retrieved by this study will cover relevant information gaps in the strongyloidiasis management among immunosuppressed patients.es_ES
dc.description.peerreviewedSíes_ES
dc.description.sponsorshipThe present work was supported by the 2020 Research Grant from the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC).es_ES
dc.format.number7es_ES
dc.format.page812es_ES
dc.format.volume10es_ES
dc.identifier.citationPathogens. 2021;10(7):812.es_ES
dc.identifier.doi10.3390/pathogens10070812es_ES
dc.identifier.issn2076-0817es_ES
dc.identifier.journalPathogens (Basel, Switzerland)es_ES
dc.identifier.pubmedID34199000es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/13984
dc.language.isoenges_ES
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI)
dc.relation.publisherversionhttps://doi.org/10.3390/pathogens10070812es_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectPCRes_ES
dc.subjectStrongyloides stercoralises_ES
dc.subjectImmunosuppressiones_ES
dc.subjectIvermectines_ES
dc.subjectPopulation pharmacokineticses_ES
dc.titleEffectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocoles_ES
dc.typejournal articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication2036bb40-097f-406a-b634-f77164674c2b
relation.isAuthorOfPublication.latestForDiscovery2036bb40-097f-406a-b634-f77164674c2b
relation.isFunderOfPublication0494be64-f7f4-4726-bed2-1a2d136fd8e0
relation.isFunderOfPublication.latestForDiscovery0494be64-f7f4-4726-bed2-1a2d136fd8e0
relation.isPublisherOfPublication30293a55-0e53-431f-ae8c-14ab01127be9
relation.isPublisherOfPublication.latestForDiscovery30293a55-0e53-431f-ae8c-14ab01127be9

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
EffectivenessAndSafetyOf_2021.pdf
Size:
231.75 KB
Format:
Adobe Portable Document Format
Description:
Download

Collections

Centro Nacional de Microbiología (CNM)
IRYCIS - Instituto Ramón y Cajal de Investigación Sanitaria (Madrid)